About Cognition Therapeutics
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company dedicated to developing groundbreaking therapies for neurodegenerative disorders. Their focus includes conditions such as Alzheimer’s disease, Dementia with Lewy Bodies, and Dry Age-related Macular Degeneration. The company is advancing first-in-class small molecule therapeutics, with their leading candidate, CT1812, demonstrating encouraging results in clinical trials. This progress opens up new possibilities for improved treatment options for patients.
Upcoming Investor Conferences
Cognition Therapeutics is preparing to take part in two important investor conferences this September. These events are crucial for the company to engage with investors, provide updates on their clinical programs, and outline future plans.
Chardan Capital Markets Leadership Call
The first event on their calendar is the Chardan Capital Markets Leadership Call, set for September 5, 2024, at 11:00 AM ET. This virtual call will offer insights into the company’s recent developments and strategic goals. Those interested in attending can register by emailing corpaccess@chardan.com.
H.C. Wainwright 26th Annual Global Investment Conference
The second conference is the esteemed H.C. Wainwright 26th Annual Global Investment Conference, which will occur from September 9-11, 2024. A webcast of the event will be accessible starting on September 9th at 7:00 AM ET, allowing a wider audience of investors to learn about Cognition's advancements.
Recent Progress in Alzheimer's Research
CEO Lisa Ricciardi highlighted the significance of these events, noting that the recent findings from the Phase 2 SHINE study revealed that their orally administered CT1812 slowed the progression of mild-to-moderate Alzheimer’s disease after just six months of treatment. This innovative therapy brings hope to patients and families grappling with this challenging condition.
Engaging with Investors
These conferences serve as vital platforms for Cognition Therapeutics to keep investors informed and engaged as they diligently work to enhance their clinical programs. With the anticipated results of the SHIMMER Phase 2 study expected by the end of the year, these discussions will play a crucial role in shaping the company’s future direction.
Contact Information for Cognition Therapeutics
For further inquiries, investors and interested parties can reach out through the following contacts:
Cognition Therapeutics, Inc.
Email: info@cogrx.com
Media Contact:
Casey McDonald
Tiberend Strategic Advisors, Inc.
Email: cmcdonald@tiberend.com
Investor Contact:
Mike Moyer
LifeSci Advisors
Email: mmoyer@lifesciadvisors.com
Frequently Asked Questions
What is Cognition Therapeutics known for?
Cognition Therapeutics specializes in developing first-in-class therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer’s.
What key events is Cognition Therapeutics participating in?
The company is set to participate in the Chardan Capital Markets Leadership Call and the H.C. Wainwright Annual Global Investment Conference.
What recent advancements has Cognition Therapeutics achieved?
The Phase 2 SHINE study has shown that CT1812 can slow the progression of Alzheimer’s disease.
How can I attend Cognition Therapeutics’ investor conferences?
Interested individuals can register via email for events like the Chardan Capital Markets Leadership Call.
Who can I contact for more information?
For further inquiries, you can contact Cognition Therapeutics using the email addresses provided above, depending on whether you are an investor or a media representative.
